精品久久久久久,在线观看精品国产,久久不卡,久久就是精品,国产精品无码久久久久,亚洲日本一区二区三区高清在线,亚洲午夜精品一级在线

熱門搜索:A549    293T 金黃色葡萄球菌 大腸桿菌 AKK菌
購(gòu)物車 1 種商品 - 共0元
當(dāng)前位置: 首頁(yè) > ATCC代理 > CLN H11.4
最近瀏覽歷史
聯(lián)系我們
  • 0574-87157013
  • [email protected]
  • 浙江省寧波市鎮(zhèn)海區(qū)莊市街道興莊路9號(hào)
  • 創(chuàng)e慧谷42號(hào)樓B幢401室
CLN H11.4
CLN H11.4
規(guī)格:
貨期:
編號(hào):B164268
品牌:Mingzhoubio

標(biāo)準(zhǔn)菌株
定量菌液
DNA
RNA

規(guī)格:
凍干粉
斜面
甘油
平板


產(chǎn)品名稱 CLN H11.4
商品貨號(hào) B164268
Organism human (B cell); human (myeloma)
Cell Type hybridoma: B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2 Cells contain EBV viral nucleic acid sequences

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease a regional draining lymph node of a patient with squamous cell carcinoma of the cervix.,a regional draining lymph node of a patient with squamous cell carcinoma of the cervix.
Applications
The antibody reacted with carcinomas of the cervix (CaSki, HeLa), prostate (PC-3), breast (ZR-76-1), colon (COLO-205) and melanoma (G-361) but was negative for normal fibroblasts (WI-38 and MRC-9), T. lymphocytes and peripheral blood lymphocytes.
The antibody may be useful in therapy and diagnosis, both in vitro and in vivo.
Storage Conditions liqid nitrogen vapor temperature
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Derivation
Lymphocytes were isolated from a regional draining lymph node of a patient with squamous cell carcinoma of the cervix.
B lymphocytes were fused with UC 729-6 cells (see ATCC CRL-8061).
Clinical Data
Lymphocytes were isolated from a regional draining lymph node of a patient with squamous cell carcinoma of the cervix.
The antibody may be useful in therapy and diagnosis, both in vitro and in vivo.
Genes Expressed
immunoglobulin; monoclonal antibody; against human cervical carcinoma
Cellular Products
immunoglobulin; monoclonal antibody; against human cervical carcinoma
Comments
The fusion line, CRL-8061, is reported to be EBNA positive.
Lymphocytes were isolated from a regional draining lymph node of a patient with squamous cell carcinoma of the cervix.
B lymphocytes were fused with UC 729-6 cells (see ATCC CRL-8061).
The antibody reacted with carcinomas of the cervix (CaSki, HeLa), prostate (PC-3), breast (ZR-76-1), colon (COLO-205) and melanoma (G-361) but was negative for normal fibroblasts (WI-38 and MRC-9), T. lymphocytes and peripheral blood lymphocytes.
The antibody may be useful in therapy and diagnosis, both in vitro and in vivo.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
Subculturing
Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml. Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cryopreservation
Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liqid nitrogen vapor temperature
Culture Conditions
Temperature: 37.0°C
Isotype IgG1; kappa light chain; human RefAotsuka Y, Hagiwara H. Identification of a malignant cell associated antigen recognized by a human monoclonal antibody. Eur. J. Cancer Clin. Oncol. 24: 829-838, 1988. PubMed: 3049115
Name of Depositor Gildred Cancer Center
U.S. Patent Number
References

Handley HH, et al. Methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies. US Patent 6,051,387 dated Apr 18 2000

Handley HH, et al. Human-human hybridom for neoplasms CLNH5 and CLNH11 specific antibody compositions. US Patent 6,051,229 dated Apr 18 2000

Handley HH, et al. CLNH11-specific antibodies. US Patent 6,051,693 dated Apr 18 2000

Hagiwara H, Sato GH. Human X human hybridoma producing monoclonal antibody against autologous cervical carcinoma. Mol. Biol. Med. 1: 245-252, 1983. PubMed: 6334217

Aotsuka Y, Naito M. Enhancing effects of retinoic acid on monoclonal antibody production of human-human hybridomas. Cell. Immunol. 133: 498-505, 1991. PubMed: 2015633

Aotsuka Y, Hagiwara H. Identification of a malignant cell associated antigen recognized by a human monoclonal antibody. Eur. J. Cancer Clin. Oncol. 24: 829-838, 1988. PubMed: 3049115

Aotsuka Y, Hagiwara H. Identification of a malignant cell associated antigen recognized by a human monoclonal antibody. Eur. J. Cancer Clin. Oncol. 24: 829-838, 1988. PubMed: 3049115

梅經(jīng)理 17280875617 1438578920
胡經(jīng)理 13345964880 2438244627
周經(jīng)理 17757487661 1296385441
于經(jīng)理 18067160830 2088210172
沈經(jīng)理 19548299266 2662369050
李經(jīng)理 13626845108 972239479
和林格尔县| 寿阳县| 盐源县| 曲周县| 东乌| 怀柔区| 洛川县| 琼海市| 新郑市| 瑞安市| 中阳县| 察隅县| 玉环县| 东山县| 都昌县| 桃江县| 安阳市| 富宁县| 平邑县| 竹北市| 长子县| 阿鲁科尔沁旗| 乌兰浩特市| 綦江县| 安岳县| 民乐县| 清水县| 离岛区| 出国| 屯门区| 海宁市| 滦南县| 佳木斯市| 衢州市| 兰溪市| 焦作市| 石嘴山市| 恩平市| 舒城县| 河北省| 水富县|